

**IN THE SPECIFICATION:**

**Please replace the paragraph beginning at page 5, line 25 - 31 with the following amended paragraph:**

FIGURES 3A and 3B show the alignment of amino acid sequences of Rep78 among AAV-1 (SEQ ID Nos. 736, 737); AAV-6 (SEQ ID Nos. 738, 739); AAV-3 (SEQ ID Nos. 740, 741); AAV-3B (SEQ ID Nos. 742, 743); AAV-4 (SEQ ID Nos. 744, 745); AAV-2 (SEQ ID Nos. 746, 747); AAV-5 (SEQ ID Nos. 748, 749) sequences, respectively; the hit positions with 100 percent homology among the serotypes are bolded italics, where the position is different (compared to AAV-2, no. 6 in the Figure) in a particular serotype, it is in bold; a sequence indicating relative conservation of sequences among the serotypes is labeled "C".

**Please replace the paragraph beginning at page 9, line 3-19 with the following amended paragraph:**

As used herein, adeno-associated virus (AAV) is a defective and non-pathogenic parvovirus that requires co-infection with either adenovirus or herpes virus for its growth and multiplication, able of providing helper functions. A variety of serotypes are known, and contemplated herein. Such serotypes include, but are not limited to: AAV-1 (Genbank accession no. NC002077; accession no. VR-645); AAV-2 (Genbank accession no. NC001401; accession no. VR-680); AAV-3 (Genbank accession no. NC001729; ~~accession~~ accession no. VR-681); AAV-3b (Genbank accession no. NC001863); AAV-4 (Genbank accession no. NC001829; ATCC accession no. VR-646 ); AAV-6 (Genbank accession no. ~~NC001729~~; NC001862); and avian associated adeno-virus (ATCC accession no. VR-1449). The preparation and use of AAVs as vectors for gene expression in vitro and for in vivo use for gene therapy is well known (see, e.g., U.S. Patent Nos. 4,797,368, 5,139,941, 5,798,390 and 6,127,175; Tessier *et al.* (2001) J. Virol. 75:375-383; Salvetti *et al.* (1998) Hum Gene Ther 20:695-706; Chadeuf *et al.* (2000) J Gene Med 2:260-268).